The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
The webinar series will showcase next-gen imaging technologies, global expert insights, and hands-on sessions on microscopy innovations
The agreements aim to strengthen medicine quality, patient safety and pharmaceutical research in India
Multi-stakeholder initiative highlights inclusive sports pathways, honours neurodivergent athletes, and calls for systemic reforms
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Collaboration integrates SmartChip PCR technology with cloud-based analytics to enable faster, standardised monitoring of antimicrobial resistance
Extending production capabilities to the Americas helps reduce labor costs and inventory complexity for nutraceuticals and other industries while maintaining superior moisture control
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
C. P. Radhakrishnan urged graduates to uphold ethical standards and maintain a commitment to patient care
Subscribe To Our Newsletter & Stay Updated
